Astrazeneca PLC Press Releases

AZN 
$27.86
*  
1.43
4.88%
Get AZN Alerts
*Delayed - data as of Jun. 24, 2016  -  Find a broker to begin trading AZN now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing

Roger Ulrich Joins Board of Remedy Pharmaceuticals
6/21/2016 10:00:00 AM - Business Wire


AstraZeneca Introduces AZhelps, an Innovative Savings and Support Program to Help Patients with Their Medicines
6/14/2016 8:00:00 AM - Business Wire
▲3.03 % Price Change since this news event. The Volume Ratio is 1.56.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




AstraZeneca Presents Findings from Two Pooled Analyses at the 76th Scientific Sessions of the American Diabetes Association Evaluating Dapagliflozin in Type 2 Diabetes Patients with Renal Impairment and in Combination with Potassium-Sparing Agents
6/11/2016 11:00:00 AM - Business Wire
▼-0.57 % Price Change since this news event. The Volume Ratio is 0.97.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes
6/11/2016 11:00:00 AM - Business Wire
▼-0.57 % Price Change since this news event. The Volume Ratio is 0.97.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




AstraZeneca to Highlight Scientific Advancements Across Its Diabetes Portfolio at the American Diabetes Association 76th Scientific Sessions
6/8/2016 8:00:00 AM - Business Wire
▼-7.13 % Price Change since this news event. The Volume Ratio is 1.22.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Tagrisso (Osimertinib) Shows Clinical Activity in Patients with Leptomeningeal Disease from Lung Cancer
6/6/2016 12:38:00 PM - Business Wire
▼-6.98 % Price Change since this news event. The Volume Ratio is 0.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer
6/5/2016 11:50:00 AM - Business Wire
▼-6.29 % Price Change since this news event. The Volume Ratio is 0.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Durvalumab Monotherapy Demonstrates Efficacy in Urothelial Bladder Cancer
6/5/2016 10:42:00 AM - Business Wire
▼-6.29 % Price Change since this news event. The Volume Ratio is 0.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Gradual Transfer of M6 Mobile Customers to Orange Services
5/27/2016 12:18:00 PM - Business Wire




AstraZeneca Highlights Continued Progress of Oncology Pipeline at ASCO 2016 Leadership in DNA Damage Response Therapies
5/19/2016 7:00:00 AM - Business Wire
▼-2.52 % Price Change since this news event. The Volume Ratio is 0.85.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AstraZeneca Announces Positive Results from Benralizumab Phase III Program in Severe Asthma
5/17/2016 7:00:00 AM - Business Wire
▼-4.43 % Price Change since this news event. The Volume Ratio is 0.68.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






BEVESPI AEROSPHERE(TM) Approved by the US FDA for Patients With COPD
4/25/2016 7:36:00 PM - Marketwired
▼-8.66 % Price Change since this news event. The Volume Ratio is 1.04.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
4/21/2016 9:15:00 AM - PR Newswire
▼-6.89 % Price Change since this news event. The Volume Ratio is 1.07.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




AstraZeneca Presents DNA Damage Response Science at the AACR 2016 Annual Meeting
4/18/2016 2:00:00 AM - Business Wire
▼-6.23 % Price Change since this news event. The Volume Ratio is 1.87.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day